![Benson Cheng](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Benson Cheng
Chief Operating Officer at Epicrispr Biotechnologies, Inc.
Benson Cheng active positions
Companies | Position | Start | End |
---|---|---|---|
Epicrispr Biotechnologies, Inc.
![]() Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | Chief Operating Officer | - | - |
Career history of Benson Cheng
Statistics
International
United States | 2 |
Operational
Chief Operating Officer | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Epicrispr Biotechnologies, Inc.
![]() Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | Commercial Services |
- Stock Market
- Insiders
- Benson Cheng
- Experience